代谢体学市场－全球产业规模、份额、趋势、机会及预测（依产品、适应症、应用、地区及竞争格局划分，2021-2031年）

全球代谢体学市场预计将从 2025 年的 34.8 亿美元成长到 2031 年的 58.4 亿美元，复合年增长率为 9.01%。

代谢体学是对小分子化合物（或称为「代谢物」）进行全面的科学分析，这些代谢物是存在于生物样本（例如体液、组织和细胞）中的代谢中间体和产物。该市场的成长主要受个人化医疗需求的不断增长以及迫切需要寻找新的生物标记来管理日益增多的慢性疾病的驱动。此外，该领域也受益于药物研发领域的大量投资，这些投资利用代谢谱分析来加速药物测试和发现。根据代谢体学学会2024年发布的公告，该组织拥有来自40多个国家的1000多名会员，这表明该行业拥有不断扩大的合作网络和全球专业知识支持。

儘管发展势头强劲，但该市场仍面临诸多挑战：高维度资料分析的复杂性以及缺乏通用标准化的资料库。先进仪器产生的大量资讯需要复杂的生物资讯工具和高技能专家进行解读，造成技术瓶颈。这项挑战可能会减缓研究成果转化为常规临床应用的进程，并可能阻碍市场的进一步扩张。

市场驱动因素

製药和生物製药行业研发投入的不断增长是全球代谢生物分析市场的主要驱动力。各公司正逐步将代谢谱分析纳入先导化合物发现流程，以改善先导化合物优化和毒性评估，而这笔巨额资金投入也推动了高分辨率质谱和核磁共振等必要技术的应用。这项投资规模庞大；例如，罗氏在2024年2月发布的2023年度报告中揭露，其研发总支出高达132亿瑞士法郎，凸显了生命科学研究领域巨额资金的涌入。此外，布鲁克在2024年宣布，2023财年的销售额将达到29.6亿美元，显示市场对支持代谢生物分析的科学工具的需求持续强劲。

慢性疾病的日益增多，既加速了生物标记发现的需求，也推动了市场成长。代谢体学提供了一种独特的观点，可以从分子水平检测表型变化，因此对于识别癌症等疾病的早期诊断标记至关重要。随着疾病负担的加重，开发精准诊断方法的压力也与日俱增。根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》，预计仅在美国就将新增2,001,140例癌症病例，这凸显了临床上迫切需要可靠的代谢生物标记来改善患者分层和治疗效果。

市场挑战

全球代谢生物化学市场成长的主要障碍在于高维度资料分析的复杂性以及缺乏通用标准化的资料库。儘管先进的分析仪器能够产生庞大而复杂的数据集，但由于缺乏一致的参考资料库，代谢物的准确鑑定效率低下且结果易受差异影响。这种标准化的缺失导致研究工作分散，难以比较不同实验室和研究的数据。因此，将代谢发现转化为可靠且可重复的临床生物标记的过程被显着延缓，使得製药公司和临床医生在将这些技术应用于常规诊断时犹豫不决。

此外，由于缺乏能够运用先进生物资讯学工具的人才，该领域面临严重的瓶颈。分析技术的快速发展速度超过了训练有素的专业人员的供给速度，而这些专业人员需要能够解读由此产生的生物数据。根据 OBN 2024 年的一项调查，超过 36% 的生命科学雇主表示，他们缺乏充分利用新兴数据技术所需的技能。这种严重的人才短缺直接限制了该行业充分利用代谢组学分析的效用，减缓了代谢组学融入主流医疗保健的进程，并阻碍了其更广泛的市场扩张。

市场趋势

人工智慧 (AI) 和机器学习在数据分析领域的快速融合，正从根本上重塑全球代谢体学市场，其关键瓶颈在于高维度数据的复杂性。随着代谢体学资料集规模日益庞大、结构日益复杂，传统的人工解读方式已无法满足需求，因此亟需藉助人工智慧驱动的演算法来实现代谢物自动识别、批次效应归一化以及细微生物学模式的发现。这种技术变革并非仅仅停留在理论层面，它正在积极推动生命科学领域的营运投资。根据英伟达 (NVIDIA) 于 2025 年 7 月发布的报告《医疗保健和生命科学领域的人工智慧现状：2025 年趋势》，78% 的受访行业人士计划在 2025 年增加人工智慧预算，这反映出企业正明显转向采用计算解决方案来提高体学研究的速度和准确性。

同时，空间代谢成像和质谱技术的出现正在改变市场格局，它能够可视化活体组织环境中的代谢物分布。与将样本均质化的总体分析不同，空间代谢成像保留了分子的组织学定位，从而为肿瘤微环境和细胞异质性提供了前所未有的洞察。主要仪器製造商正透过收购专业的太空生物学平台并将其整合到现有的质谱产品组合中，来满足这一市场需求并扩大收入。根据布鲁克公司于2025年2月发布的2024年度报告，该公司在2024财年实现了超过33亿美元的公司营收。这项财务里程碑主要归功于其太空生物学部门的策略扩张以及公司新型高通量成像技术的应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球代谢体学市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（代谢体学设备、代谢体学物资讯学工具及服务）
  • 按适应症（癌症、心血管疾病、神经系统疾病、先天性代谢疾病等）
  • 依应用领域（生物标记/药物发现、毒理学、营养基因体学、个人化医疗等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美代谢体学市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲代谢体学市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区代谢体学市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲代谢体学市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲代谢体学市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球代谢体学市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Metabolon, Inc.
• Agilent Technologies, Inc.
• Bruker Corporation
• Human Metabolome Technologies America, Inc.
• Thermo Fisher Scientific Inc.
• Shimadzu Corporation
• Danaher Corporation
• Waters Corporation
• Metware Biotechnology Inc.
• Afekta Technologies Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Metabolomics Market is anticipated to expand from USD 3.48 Billion in 2025 to USD 5.84 Billion by 2031, registering a CAGR of 9.01%. Metabolomics is defined as the exhaustive scientific examination of metabolites, which are the small-molecule intermediates and byproducts of metabolism present in biological samples like biofluids, tissues, and cells. The growth of this market is primarily fueled by the increasing demand for personalized medicine and the urgent necessity to identify novel biomarkers for managing the growing prevalence of chronic diseases. Furthermore, the sector benefits from significant investments in pharmaceutical research and development, which employ metabolic profiling to expedite toxicology testing and drug discovery. As noted by the Metabolomics Society in 2024, the organization included more than 1,000 members from over 40 countries, illustrating the widening collaborative network and global expertise supporting this industry.

Despite these driving forces, the market encounters a major obstacle regarding the intricacy of high-dimensional data analysis and the absence of universally standardized databases. The immense volume of information produced by advanced instrumentation necessitates sophisticated bioinformatics tools and highly skilled professionals for interpretation, resulting in a technical bottleneck. This challenge threatens to delay the translation of research findings into routine clinical applications and could hinder broader market expansion.

Market Driver

Increasing research and development expenditure within the pharmaceutical and biopharmaceutical sectors serves as a major catalyst for the Global Metabolomics Market. Companies are progressively incorporating metabolic profiling into their drug development processes to improve lead optimization and toxicity assessment, a financial commitment that enables the deployment of essential high-resolution mass spectrometry and nuclear magnetic resonance technologies. The scale of this investment is significant; for example, Roche reported a total R&D spend of CHF 13.2 billion in its 2023 Annual Report published in February 2024, emphasizing the massive capital entering life sciences research. Additionally, Bruker Corporation reported fiscal year 2023 revenues of $2.96 billion in 2024, reflecting persistent industrial demand for the scientific tools that underpin metabolomic analysis.

The growing prevalence of chronic diseases is simultaneously accelerating the need for biomarker discovery, thereby propelling market growth. Metabolomics provides a distinct vantage point by detecting phenotypic changes at the molecular level, making it essential for identifying early diagnostic markers for conditions such as cancer. As the disease burden increases, the pressure to develop precision diagnostics intensifies. According to the American Cancer Society's 'Cancer Facts & Figures 2024' released in January 2024, it is projected that there will be 2,001,140 new cancer cases in the United States alone, highlighting the urgent clinical need for robust metabolic biomarkers to improve patient stratification and treatment outcomes.

Market Challenge

The primary hurdle restricting the growth of the Global Metabolomics Market is the complexity associated with high-dimensional data analysis combined with the lack of universally standardized databases. As advanced instrumentation produces massive and intricate datasets, the absence of consistent reference libraries renders the accurate identification of metabolites inefficient and prone to variability. This standardization deficit fragments research efforts, making data difficult to compare across different laboratories or studies. Consequently, the translation of metabolic discoveries into reliable, reproducible clinical biomarkers is significantly stalled, causing pharmaceutical companies and clinicians to hesitate in adopting these technologies for routine diagnostic applications.

Moreover, this sector faces a critical bottleneck due to a shortage of personnel capable of navigating sophisticated bioinformatics tools. The rapid evolution of analytical technologies has outpaced the supply of experts trained to interpret the resulting biological data. According to OBN in 2024, over 36% of life sciences employers reported they did not have access to the right skills to fully leverage emerging data technologies. This acute talent gap directly restricts the industry's capacity to maximize the utility of metabolic profiling, thereby slowing the integration of metabolomics into mainstream healthcare and limiting broader market expansion.

Market Trends

The rapid integration of Artificial Intelligence and Machine Learning for Data Analysis is fundamentally reshaping the Global Metabolomics Market by addressing the critical bottleneck of high-dimensional data complexity. As metabolomic datasets become increasingly voluminous and intricate, traditional manual interpretation is proving insufficient, necessitating AI-driven algorithms to automate metabolite identification, normalize batch effects, and uncover subtle biological patterns. This technological shift is not merely theoretical but is actively driving operational investment across the life sciences sector. According to NVIDIA's 'State of AI in Healthcare and Life Sciences: 2025 Trends' report from July 2025, 78% of industry respondents indicated that their artificial intelligence budgets would grow in 2025, reflecting a decisive pivot toward computational solutions to enhance the speed and accuracy of omics research.

Simultaneously, the emergence of Spatial Metabolomics and Mass Spectrometry Imaging is transforming the market by enabling the visualization of metabolite distribution within the native tissue context. Unlike bulk analysis, which homogenizes samples, spatial metabolomics preserves the histological localization of molecules, offering unprecedented insights into tumor microenvironments and cellular heterogeneity. Leading instrument manufacturers are capitalizing on this demand by acquiring specialized spatial biology platforms and integrating them into their existing mass spectrometry portfolios to drive revenue. According to Bruker Corporation's 'Annual Report 2024' released in February 2025, the company delivered fiscal year 2024 revenues of over $3.3 billion, a financial milestone attributed significantly to the strategic expansion of its spatial biology division and the adoption of its novel high-plex imaging technologies.

Key Market Players

• Metabolon, Inc.
• Agilent Technologies, Inc.
• Bruker Corporation
• Human Metabolome Technologies America, Inc.
• Thermo Fisher Scientific Inc.
• Shimadzu Corporation
• Danaher Corporation
• Waters Corporation
• Metware Biotechnology Inc.
• Afekta Technologies Ltd.

Report Scope

In this report, the Global Metabolomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolomics Market, By Product

• Metabolomics Instruments
• Metabolomics Bioinformatics Tools & Services

Metabolomics Market, By Indication

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Inborn Errors of Metabolism
• Others

Metabolomics Market, By Application

• Biomarker and Drug Discovery
• Toxicology
• Nutrigenomics
• Personalized Medicine
• Others

Metabolomics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolomics Market.

Available Customizations:

Global Metabolomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metabolomics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services)
  • 5.2.2. By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Others)
  • 5.2.3. By Application (Biomarker and Drug Discovery, Toxicology, Nutrigenomics, Personalized Medicine, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Metabolomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metabolomics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Metabolomics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Metabolomics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Application

7. Europe Metabolomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metabolomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Application
  • 7.3.2. France Metabolomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Metabolomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Metabolomics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Metabolomics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Application

8. Asia Pacific Metabolomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Metabolomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Application
  • 8.3.2. India Metabolomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Metabolomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Metabolomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Metabolomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Application

9. Middle East & Africa Metabolomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Indication
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Metabolomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Metabolomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Metabolomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Application

10. South America Metabolomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Indication
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Metabolomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Metabolomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Metabolomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Metabolomics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Metabolon, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies, Inc.
• 15.3. Bruker Corporation
• 15.4. Human Metabolome Technologies America, Inc.
• 15.5. Thermo Fisher Scientific Inc.
• 15.6. Shimadzu Corporation
• 15.7. Danaher Corporation
• 15.8. Waters Corporation
• 15.9. Metware Biotechnology Inc.
• 15.10. Afekta Technologies Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer